10x Genomics, Inc. (TXG) stock
TXGNasdaqLaboratory Analytical InstrumentsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 6, 2026Score 9/30111% above fair value
$57.07+0.77 (+1.37%)
Close on Nov 18, 2026Market cap $7.44BP/E –Yield –
10x Genomics revenue
Revenue is the money a company takes in from selling its products and services, before any costs are deducted.
10x Genomics's revenue for the twelve months ending Sep 30, 2026 was $618.58M, down 3.6% year over year. For fiscal 2025 it was $642.82M, up 5.2% from the year before. The highest annual figure on record is $642.82M in fiscal 2025.
Annual revenue
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $642.82M | +5.2% |
| FY2024 | Dec 31, 2024 | $610.79M | -1.3% |
| FY2023 | Dec 31, 2023 | $618.73M | +19.8% |
| FY2022 | Dec 31, 2022 | $516.41M | +5.3% |
| FY2021 | Dec 31, 2021 | $490.49M | +64.1% |
| FY2020 | Dec 31, 2020 | $298.85M | +21.5% |
| FY2019 | Dec 31, 2019 | $245.89M | +68.1% |
| FY2018 | Dec 31, 2018 | $146.31M | +105.8% |
| FY2017 | Dec 31, 2017 | $71.09M | – |
Quarterly revenue
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | $150.67M | +1.1% |
| Q2 FY2026 | Jun 30, 2026 | $151.04M | -12.6% |
| Q1 FY2026 | Mar 31, 2026 | $150.84M | -2.6% |
| Q4 FY2025 | Dec 31, 2025 | $166.03M | +0.6% |
| Q3 FY2025 | Sep 30, 2025 | $149.00M | -1.7% |
| Q2 FY2025 | Jun 30, 2025 | $172.91M | +12.9% |
| Q1 FY2025 | Mar 31, 2025 | $154.88M | +9.8% |
| Q4 FY2024 | Dec 31, 2024 | $165.02M | -10.3% |
| Q3 FY2024 | Sep 30, 2024 | $151.65M | -1.3% |
| Q2 FY2024 | Jun 30, 2024 | $153.10M | +4.3% |
| Q1 FY2024 | Mar 31, 2024 | $141.01M | +5.0% |
| Q4 FY2023 | Dec 31, 2023 | $183.98M | +17.8% |
| Q3 FY2023 | Sep 30, 2023 | $153.64M | +17.2% |
| Q2 FY2023 | Jun 30, 2023 | $146.82M | +28.1% |
| Q1 FY2023 | Mar 31, 2023 | $134.29M | +17.3% |
| Q4 FY2022 | Dec 31, 2022 | $156.23M | +8.8% |
| Q3 FY2022 | Sep 30, 2022 | $131.07M | +4.6% |
| Q2 FY2022 | Jun 30, 2022 | $114.61M | -1.1% |
| Q1 FY2022 | Mar 31, 2022 | $114.50M | +8.2% |
| Q4 FY2021 | Dec 31, 2021 | $143.53M | +27.9% |
| Q3 FY2021 | Sep 30, 2021 | $125.30M | +74.5% |
| Q2 FY2021 | Jun 30, 2021 | $115.84M | +170.0% |
| Q1 FY2021 | Mar 31, 2021 | $105.82M | +47.2% |
| Q4 FY2020 | Dec 31, 2020 | $112.22M | +49.0% |
| Q3 FY2020 | Sep 30, 2020 | $71.82M | +17.3% |
| Q2 FY2020 | Jun 30, 2020 | $42.91M | -23.1% |
| Q1 FY2020 | Mar 31, 2020 | $71.91M | +34.2% |
| Q4 FY2019 | Dec 31, 2019 | $75.29M | +48.9% |
| Q3 FY2019 | Sep 30, 2019 | $61.21M | +67.2% |
| Q2 FY2019 | Jun 30, 2019 | $55.82M | +75.8% |
| Q1 FY2019 | Mar 31, 2019 | $53.58M | +95.5% |
| Q4 FY2018 | Dec 31, 2018 | $50.55M | – |
| Q3 FY2018 | Sep 30, 2018 | $36.61M | – |
| Q2 FY2018 | Jun 30, 2018 | $31.74M | – |
| Q1 FY2018 | Mar 31, 2018 | $27.41M | – |
See a number that looks wrong?